`Date filed: June 29, 2017
`
`
`Filed On Behalf Of:
`
`Novartis AG
`
`By:
`
`Nicholas N. Kallas
`NKallas@fchs.com
`ZortressAfinitorIPR@fchs.com
`(212) 218-2100
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`ARGENTUM PHARMACEUTICALS LLC,
`Petitioner,
`
`v.
`
`NOVARTIS AG,
`Patent Owner.
`
`
`
`Case IPR2017-01063
`Patent 9,006,224
`
`
`
`
`WAIVER OF PATENT OWNER’S PRELIMINARY RESPONSE
`
`
`
`
`
`
`
`
`
`
`Pursuant to 37 C.F.R. § 42.107(b), Patent Owner Novartis AG hereby elects
`
`to waive its preliminary response in this Inter Partes Review No. 2017-01063. As
`
`indicated in the Trial Practice Guide, no adverse inference should be taken by this
`
`election. See Office Trial Practice Guide, Fed. Reg. Vol. 77, No. 157 (2012) at
`
`Section II.C. This election shall not constitute a waiver or admission by Patent
`
`Owner with respect to any material set forth in the Petition.
`
`Respectfully submitted,
`
`/ Nicholas N. Kallas /
`Nicholas N. Kallas
`Registration No. 31,530
`Lead Counsel for Patent Owner
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`
`
`
`
`Dated: June 29, 2017
`
`
`
`
`
`1
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`
`
`I certify that a copy of the foregoing Waiver Of Patent Owner’s Preliminary
`
`Response was served on June 29, 2017 by causing it to be sent by email to counsel
`
`for Petitioner at the following email addresses:
`
`Kevin Laurence (klaurence@lpiplaw.com)
`
`Matthew Phillips (mphillips@lpiplaw.com)
`
`Tyler C. Liu (tliu@agpharm.com)
`
`
`
`Dated: June 29, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/ Nicholas N. Kallas /
`Nicholas N. Kallas
`Registration No. 31,530
`FITZPATRICK, CELLA, HARPER
`& SCINTO
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`
`
`
`
`
`
`2
`
`